MedPath

Validation of Chlamydia Diagnostic Codes in TriNetX US EHR Data

Recruiting
Conditions
Chlamydial Infections
Registration Number
NCT07094373
Lead Sponsor
Sanofi
Brief Summary

This study is a pharmacoepidemiologic method study based on the secondary use of pre-existing data that examines whether TriNetX, a global health research network encompassing a worldwide electronic health record (EHR), database in the US is an appropriate real-world data (RWD) source for conducting chlamydia-related research to support the chlamydia trachomatis (CT) messenger Ribonucleic acid (mRNA) vaccine program.

There are two primary objectives for this study:

1. To determine the validity of ICD, Tenth Revision, Clinical Modification (ICD-10-CM) diagnostic codes to identify patients with chlamydial infections using TriNetX EHR data in the US

2. To describe screening or diagnostic testing and treatment patterns in patients with chlamydia using TriNetX EHR data in the US

There are also two secondary objectives for this study:

1. To explore the feasibility of developing a modified algorithm for identifying patients with chlamydia applicable for Merative MarketScan Commercial Claims and Encounters (CCAE) database based on the findings from the primary objectives

2. To compare patient characteristics, use of screening or diagnostic testing, and treatment patterns among patients with chlamydia between TriNetX EHR data and the MarketScan CCAE data in the US

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
533000
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Validity of ICD-10-CM Diagnostic Codes for Chlamydial InfectionsFrom year 2016 through year 2024

Diagnostic performance of ICD-10-CM codes for chlamydial infections, including sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV), compared to Nucleic Acid Amplification Test (NAAT) results for chlamydial infections

Descriptive analyses of chlamydia patientsFrom year 2016 through year 2024

Describe demographic characteristics, laboratory testing, and treatment patterns among true positive and false negative chlamydia patients

Secondary Outcome Measures
NameTimeMethod
Validity of CCAE Database for Chlamydial InfectionsFrom year 2016 through year 2023

Detect chlamydia cases using a mix of diagnostic codes, lab test codes, treatments, to detect/confirm chlamydia infection

Comparison of chlamydia patient characteristics between EHR and claims RWD sources in the USFrom year 2016 through year 2024

Compare demographics and clinical features (e.g., age, sex, treatment history, comorbidities) of chlamydia patients as seen in EHRs which contain clinical notes, lab results, and detailed medical histories and claims data

Trial Locations

Locations (1)

University of Massachusetts Medical School

🇺🇸

Worcester, Massachusetts, United States

University of Massachusetts Medical School
🇺🇸Worcester, Massachusetts, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.